2- (4- chlorophenyl)- 5- methyl- 4- (2- (4- methyl- 2- oxo- 2H- chromen- 7- yloxy)ethyl)- 2H- 1,2,4- triazol- 3(4H)- one

structure in first source

Also Known As:

NSC 761736-1

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - 2-(4-chlorophenyl)-5-methyl-4-(2-(4-methyl-2-oxo-2H-chromen-7-yloxy)ethyl)-2H-1,2,4-triazol-3(4H)-one: 1
  - Pyrans: 130
    - Benzopyrans: 195
      - Coumarins: 826
        2-(4-chlorophenyl)-5-methyl-4-(2-(4-methyl-2-oxo-2H-chromen-7-yloxy)ethyl)-2H-1,2,4-triazol-3(4H)-one: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Coumarins: 826
        2-(4-chlorophenyl)-5-methyl-4-(2-(4-methyl-2-oxo-2H-chromen-7-yloxy)ethyl)-2H-1,2,4-triazol-3(4H)-one: 1

Experts

1.	Dorababu, Atukuri: 1 article (04/2013)
2.	Hunnur, Raveendra K: 1 article (04/2013)
3.	Kamble, Ravindra R: 1 article (04/2013)
4.	Kariduraganavar, Mahadevappa Y: 1 article (04/2013)
5.	Kattimani, Pramod P: 1 article (04/2013)

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 04/01/2013 - "Among the tested compounds (5a-e, 5g-h, 5k, 5p), the compound 5g (NSC: 761736/1) was further evaluated for five dose criteria at five different minimal concentrations against the full panel of 60 human tumor cell lines which exhibited activity against Leukemia (GI50: 1.10 μM), Non-Small Cell Lung Cancer (GI50: 1.00 μM), Renal Cancer (GI50: 1.00 μM), Colon Cancer (GI50: 1.66 μM), CNS Cancer (GI50: 1.36 μM), Melanoma (GI50: 1.82 μM), Ovarian Cancer (GI50: 1.64 μM) and Breast Cancer (GI50: 1.69 μM)."
2.	Neoplasms (Cancer) 04/01/2013 - "Among the tested compounds (5a-e, 5g-h, 5k, 5p), the compound 5g (NSC: 761736/1) was further evaluated for five dose criteria at five different minimal concentrations against the full panel of 60 human tumor cell lines which exhibited activity against Leukemia (GI50: 1.10 μM), Non-Small Cell Lung Cancer (GI50: 1.00 μM), Renal Cancer (GI50: 1.00 μM), Colon Cancer (GI50: 1.66 μM), CNS Cancer (GI50: 1.36 μM), Melanoma (GI50: 1.82 μM), Ovarian Cancer (GI50: 1.64 μM) and Breast Cancer (GI50: 1.69 μM)."
3.	Melanoma (Melanoma, Malignant) 04/01/2013 - "Among the tested compounds (5a-e, 5g-h, 5k, 5p), the compound 5g (NSC: 761736/1) was further evaluated for five dose criteria at five different minimal concentrations against the full panel of 60 human tumor cell lines which exhibited activity against Leukemia (GI50: 1.10 μM), Non-Small Cell Lung Cancer (GI50: 1.00 μM), Renal Cancer (GI50: 1.00 μM), Colon Cancer (GI50: 1.66 μM), CNS Cancer (GI50: 1.36 μM), Melanoma (GI50: 1.82 μM), Ovarian Cancer (GI50: 1.64 μM) and Breast Cancer (GI50: 1.69 μM)."
4.	Leukemia 04/01/2013 - "Among the tested compounds (5a-e, 5g-h, 5k, 5p), the compound 5g (NSC: 761736/1) was further evaluated for five dose criteria at five different minimal concentrations against the full panel of 60 human tumor cell lines which exhibited activity against Leukemia (GI50: 1.10 μM), Non-Small Cell Lung Cancer (GI50: 1.00 μM), Renal Cancer (GI50: 1.00 μM), Colon Cancer (GI50: 1.66 μM), CNS Cancer (GI50: 1.36 μM), Melanoma (GI50: 1.82 μM), Ovarian Cancer (GI50: 1.64 μM) and Breast Cancer (GI50: 1.69 μM)."
5.	Kidney Neoplasms (Kidney Cancer) 04/01/2013 - "Among the tested compounds (5a-e, 5g-h, 5k, 5p), the compound 5g (NSC: 761736/1) was further evaluated for five dose criteria at five different minimal concentrations against the full panel of 60 human tumor cell lines which exhibited activity against Leukemia (GI50: 1.10 μM), Non-Small Cell Lung Cancer (GI50: 1.00 μM), Renal Cancer (GI50: 1.00 μM), Colon Cancer (GI50: 1.66 μM), CNS Cancer (GI50: 1.36 μM), Melanoma (GI50: 1.82 μM), Ovarian Cancer (GI50: 1.64 μM) and Breast Cancer (GI50: 1.69 μM)."